Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.

Authors

Senthil Damodaran
Paul V. Plourde
Halle CF Moore
Ian Churchill Anderson, Providence
David Jay Portman

Document Type

Presentation

Publication Date

6-2-2022

Keywords

california; santa rosa

Clinical Institute

Cancer

Clinical Institute

Women & Children

Department

Oncology

Comments

2022 ASCO Annual Meeting I

Recommended Citation

Damodaran, Senthil; Plourde, Paul V.; Moore, Halle CF; Anderson, Ian Churchill; and Portman, David Jay, "Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies." (2022). Articles, Abstracts, and Reports. 6961.
https://digitalcommons.providence.org/publications/6961